Fig. 2
The forest plot of showing the effects of SGLT-2 inhibition on inflammation biomarkers and the effects of inflammation biomarkers on heart failure. A The effects of SGLT-2 inhibition on the remaining 28 selected inflammation biomarkers from 92 inflammation biomarkers, which were significantly associated with SGLT-2 inhibition. B The effects of the above 28 inflammation biomarkers on heart failure. CI confidence interval, OR odds ratio, CCL19 C–C motif chemokine 19, CCL20 C–C motif chemokine 20, CCL28 C–C motif chemokine 28, CXCL10 C-X-C motif chemokine 10, CXCL6 C-X-C motif chemokine 6, CXCL9 C-X-C motif chemokine 9, DNER Delta and Notch-like epidermal growth factor related receptor, FGF19 Fibroblast growth factor 19, FGF21 Fibroblast growth factor 21, FGF23 Fibroblast growth factor 23, IFN-γ Interferon gamma, IL − 10 Interleukin-10, IL − 12B Interleukin-12 subunit beta, IL − 22RA Interleukin-22 receptor subunit alpha-1, IL − 6 Interleukin-6, LAP TGF-β1 Latency associated peptide transforming growth factor beta 1, LIF Leukemia inhibitory factor, MCP − 1 Monocyte chemoattractant protein-1, MCP − 4 Monocyte chemoattractant protein-4, PD − L1 Programmed cell death 1 ligand 1, SULT1A1 Sulfotransferase 1A1, TNF Tumor necrosis factor, TSLP Thymic stromal lymphopoietin, uPA Urokinase type plasminogen activator, CRP C-reactive protein